Kornhuber Johannes, Schmidtke Klaus, Frolich Lutz, Perneczky Robert, Wolf Stefanie, Hampel Harald, Jessen Frank, Heuser Isabella, Peters Oliver, Weih Markus, Jahn Holger, Luckhaus Christian, Hüll Michael, Gertz Hermann-Josef, Schröder Johannes, Pantel Johannes, Rienhoff Otto, Seuchter Susanne A, Rüther Eckart, Henn Fritz, Maier Wolfgang, Wiltfang Jens
Department of Psychiatry and Psychotherapy, University Erlangen, Erlangen, Germany.
Dement Geriatr Cogn Disord. 2009;27(5):404-17. doi: 10.1159/000210388. Epub 2009 Apr 1.
The German Dementia Competence Network (DCN) has established procedures for standardized multicenter acquisition of clinical, biological and imaging data, for centralized data management, and for the evaluation of new treatments.
A longitudinal cohort study was set up for patients with mild cognitive impairment (MCI), patients with mild dementia and control subjects. The aims were to establish the diagnostic, differential diagnostic and prognostic power of a range of clinical, laboratory and imaging methods. Furthermore, 2 clinical trials were conducted with patients suffering from MCI and mild to moderate Alzheimer's Disease (AD). These trials aimed at evaluating the efficacy and safety of the combination of galantamine and memantine versus galantamine alone.
Here, we report on the scope and projects of the DCN, the methods that were employed, the composition and flow within the diverse groups of patients and control persons and on the clinical and neuropsychological baseline characteristics of the group of 2,113 subjects who participated in the observational and clinical trials.
These data have an impact on the procedures for the early and differential clinical diagnosis of dementias, the current standard treatment of AD as well as on future clinical trials in AD.
德国痴呆症能力网络(DCN)已制定了标准化多中心获取临床、生物和影像数据、集中数据管理以及评估新疗法的程序。
针对轻度认知障碍(MCI)患者、轻度痴呆患者和对照受试者开展了一项纵向队列研究。目的是确定一系列临床、实验室和影像方法的诊断、鉴别诊断及预后能力。此外,还对MCI患者和轻度至中度阿尔茨海默病(AD)患者进行了两项临床试验。这些试验旨在评估加兰他敏和美金刚联合用药与单用加兰他敏相比的疗效和安全性。
在此,我们报告DCN的范围和项目、所采用的方法、不同患者组和对照组的构成及流程,以及参与观察性和临床试验的2113名受试者的临床和神经心理学基线特征。
这些数据对痴呆症的早期和鉴别临床诊断程序、AD的当前标准治疗以及未来AD临床试验均有影响。